Abbrea Capital LLC Has $5.50 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Abbrea Capital LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 4.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 9,426 shares of the company’s stock after purchasing an additional 383 shares during the quarter. Abbrea Capital LLC’s holdings in Eli Lilly and Company were worth $5,495,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC grew its holdings in Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares during the period. Sapient Capital LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $617,312,000. J.P. Morgan Private Wealth Advisors LLC acquired a new position in Eli Lilly and Company during the third quarter valued at approximately $435,736,000. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after buying an additional 659,838 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Eli Lilly and Company by 24.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock valued at $1,778,362,000 after buying an additional 645,473 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on LLY shares. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a report on Monday, April 15th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Stock Up 1.2 %

NYSE:LLY traded up $8.64 during trading hours on Friday, reaching $733.51. The company had a trading volume of 1,998,801 shares, compared to its average volume of 3,021,262. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market cap of $696.95 billion, a price-to-earnings ratio of 126.80, a P/E/G ratio of 1.60 and a beta of 0.34. The business’s 50-day simple moving average is $762.75 and its two-hundred day simple moving average is $664.94. Eli Lilly and Company has a twelve month low of $380.77 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the firm earned $2.09 earnings per share. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. On average, equities analysts expect that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.